Diffuse alveolar hemorrhage in coumarin users: a fibrosing interstitial pneumonia trigger?

Lung. 2013 Feb;191(1):53-9. doi: 10.1007/s00408-012-9436-2. Epub 2012 Nov 13.

Abstract

Background: Fibrosing interstitial pneumonias (IPs) include idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). It has been suggested that oxidative damage plays a role in the pathophysiology of idiopathic interstitial pneumonias. Diffuse alveolar hemorrhage (DAH) can cause oxidative stress. Accordingly, we hypothesized that episodes of DAH might trigger fibrosing IP development.

Methods: Patients using coumarins with confirmed DAH were retrospectively gathered during a 9 year period and reviewed for the development of IPF or fibrosing NSIP.

Results: A total of 65 patients with DAH could finally be included, 31 (48 %) of whom subsequently developed a fibrosing IP. The majority of these 31 patients developed the fibrosing IP within 3 years after DAH confirmation. A total of 41 (63 %) patients died within 3.0 ± 0.9 (range 1.3-4.7) years after the DAH diagnosis had been confirmed. Twenty-two of the deceased (54 %) had finally developed fibrosing IP.

Conclusions: Almost half of the patients with established episodes of DAH developed fibrosing IP; therefore it seems that DAH might be a trigger for the development of fibrosing IP. This observation warrants prospective studies to further evaluate the clinical impact of these findings.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / drug therapy
  • Coumarins / therapeutic use*
  • Female
  • Hemorrhage / complications*
  • Hemorrhage / physiopathology
  • Humans
  • Lung Diseases / complications*
  • Lung Diseases / physiopathology
  • Lung Diseases, Interstitial / epidemiology
  • Lung Diseases, Interstitial / etiology*
  • Lung Diseases, Interstitial / physiopathology
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy
  • Oxidative Stress / physiology
  • Pulmonary Alveoli*
  • Pulmonary Fibrosis / epidemiology
  • Pulmonary Fibrosis / etiology*
  • Pulmonary Fibrosis / physiopathology
  • Retrospective Studies
  • Risk Factors
  • Venous Thrombosis / drug therapy

Substances

  • Anticoagulants
  • Coumarins
  • coumarin